IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Primary Biliary Cirrhosis
Newcastle-upon-Tyne Hospitals NHS Trustmonoclonal_antibodyPhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Primary Biliary Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
URSODEOXYCHOLIC ACID Xijing Hospital of Digestive Diseases | Phase 4 | A |
Fenofibrate Xijing Hospital of Digestive Diseases | Phase 3 | BB |
Saroglitazar Zydus Therapeutics Inc. | Phase 3 | BB |
Mbx-8025 Gilead Sciences | Phase 3 | BB |
Obeticholic Acid Intercept Pharmaceuticals | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →